HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metabolomic analyses uncover an inhibitory effect of niclosamide on mitochondrial membrane potential in cholangiocarcinoma cells.

AbstractBackground:
Niclosamide is an oral anthelminthic drug that has been used for treating tapeworm infections. Its mechanism involves the disturbance of mitochondrial membrane potential that in turn inhibits oxidative phosphorylation leading to ATP depletion. To date, niclosamide has been validated as the potent anti-cancer agent against several cancers. However, the molecular mechanisms underlying the effects of niclosamide on the liver fluke Opisthorchis viverrini (Ov)-associated cholangiocarcinoma (CCA) cell functions remain to be elucidated. The aims of this study were to investigate the effects of niclosamide on CCA cell proliferation and on metabolic phenoconversion through the alteration of metabolites associated with mitochondrial function in CCA cell lines.
Materials and Methods:
The inhibitory effect of niclosamide on CCA cells was determined using SRB assay. A mitochondrial membrane potential using tetramethylrhodamine, ethyl ester-mitochondrial membrane potential (TMRE-MMP) assay was conducted. Liquid chromatography-mass spectrometry-based metabolomics was employed to investigate the global metabolic changes upon niclosamide treatment. ATP levels were measured using CellTiter-Glo® luminescent cell viability assay. NAD metabolism was examined by the NAD+/NADH ratio.
Results:
Niclosamide strongly inhibited CCA cell growth and reduced the MMP of CCA cells. An orthogonal partial-least square regression analysis revealed that the effects of niclosamide on suppressing cell viability and MMP of CCA cells were significantly associated with an increase in niacinamide, a precursor in NAD synthesis that may disrupt the electron transport system leading to suppression of NAD+/NADH ratio and ATP depletion.
Conclusion:
Our findings unravel the mode of action of niclosamide in the energy depletion that could potentially serve as the promising therapeutic strategy for CCA treatment.
AuthorsThanaporn Kulthawatsiri, Yingpinyapat Kittirat, Jutarop Phetcharaburanin, Jittima Tomacha, Bundit Promraksa, Arporn Wangwiwatsin, Poramate Klanrit, Attapol Titapun, Watcharin Loilome, Nisana Namwat
JournalPeerJ (PeerJ) Vol. 11 Pg. e16512 ( 2023) ISSN: 2167-8359 [Electronic] United States
PMID38025687 (Publication Type: Journal Article)
Copyright© 2023 Kulthawatsiri et al.
Chemical References
  • Niclosamide
  • NAD
  • Adenosine Triphosphate
Topics
  • Animals
  • Niclosamide (pharmacology)
  • Opisthorchiasis (complications)
  • NAD (metabolism)
  • Membrane Potential, Mitochondrial
  • Cholangiocarcinoma (drug therapy)
  • Bile Ducts, Intrahepatic (metabolism)
  • Bile Duct Neoplasms (drug therapy)
  • Adenosine Triphosphate (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: